Johnson & Johnson
Johnson & Johnson Completed Public Offerings of Various Notes
Summary
On February 20, 2025, Johnson & Johnson completed the public offerings of various notes, including $750,000,000 aggregate principal amount of 4.500% Notes due 2027, $750,000,000 aggregate principal amount of 4.550% Notes due 2028, $1,000,000,000 aggregate principal amount of 4.700% Notes due 2030, $1,250,000,000 aggregate principal amount of 4.850% Notes due 2032, and $1,250,000,000 aggregate principal amount of 5.000% Notes due 2035, under the Company's Registration Statement on Form S-3. The offerings were made in connection with an underwriting agreement entered on February 18, 2025.
Profitelligence Alerts
Get alerts for JNJ
Be first to know when Johnson & Johnson files with the SEC.
Filing Categories
Exhibits (10)
Advertisement
About Johnson & Johnson
Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.
Official SEC Documents
Advertisement